Literature DB >> 19937125

Cardiopulmonary exercise testing in thalassemia.

John-Paul Carpenter, Dudley J Pennell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19937125     DOI： 10.1007/s10554-009-9537-z

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN： 1569-5794            Impact factor:   2.357


× No keyword cloud information.
  23 in total

1.  A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.

Authors:  M A Tanner; R Galanello; C Dessi; G C Smith; M A Westwood; A Agus; M Roughton; R Assomull; S V Nair; J M Walker; D J Pennell
Journal:  Circulation       Date:  2007-03-19       Impact factor: 29.690

2.  New insights into the exercise intolerance of beta-thalassemia major patients.

Authors:  S Nanas; I Vasileiadis; S Dimopoulos; D Sakellariou; S Kapsimalakou; O Papazachou; A Tasoulis; V Ladis; G Pangalis; A Aessopos
Journal:  Scand J Med Sci Sports       Date:  2008-02-27       Impact factor: 4.221

3.  Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance.

Authors:  Lisa J Anderson; Mark A Westwood; Sally Holden; Bernard Davis; Emma Prescott; Beatrix Wonke; John B Porter; J Malcolm Walker; Dudley J Pennell
Journal:  Br J Haematol       Date:  2004-11       Impact factor: 6.998

4.  Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy.

Authors:  John C Wood; Maya Otto-Duessel; Michelle Aguilar; Hanspeter Nick; Marvin D Nelson; Thomas D Coates; Harvey Pollack; Rex Moats
Journal:  Circulation       Date:  2005-07-18       Impact factor: 29.690

5.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.

Authors:  G M Felker; R E Thompson; J M Hare; R H Hruban; D E Clemetson; D L Howard; K L Baughman; E K Kasper
Journal:  N Engl J Med       Date:  2000-04-13       Impact factor: 91.245

6.  Myocardial and hepatic T2* magnetic resonance evaluation in ex-thalassemic patients after bone-marrow transplantation.

Authors:  Sophie Mavrogeni; Efstathios D Gotsis; Eleni Berdousi; Vasilios Ladis; Dimitrios Verganelakis; Panagiotis Toulas; Dennis V Cokkinos
Journal:  Int J Cardiovasc Imaging       Date:  2007-01-19       Impact factor: 2.357

7.  Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium.

Authors:  D H Fitchett; D J Coltart; W A Littler; M J Leyland; T Trueman; D I Gozzard; T J Peters
Journal:  Cardiovasc Res       Date:  1980-12       Impact factor: 10.787

Review 8.  Cardiopulmonary exercise testing and its application.

Authors:  K Albouaini; M Egred; A Alahmar; D J Wright
Journal:  Heart       Date:  2007-10       Impact factor: 5.994

9.  Multi-center transferability of a breath-hold T2 technique for myocardial iron assessment.

Authors:  Taigang He; Paul Kirk; David N Firmin; Wynnie M Lam; Winnie C W Chu; Wing-Yan Au; Godfrey C F Chan; Ru San Tan; Ivy Ng; Selen Biceroglu; Yesim Aydinok; Mark A Fogel; Alan R Cohen; Dudley J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2008-02-21       Impact factor: 5.364

10.  T2 relaxation time study of iron overload in b-thalassemia.

Authors:  S I Mavrogeni; E D Gotsis; V Markussis; N Tsekos; C Politis; E Vretou; D Kermastinos
Journal:  MAGMA       Date:  1998-08       Impact factor: 2.533
View more
  2 in total

1.  Cardiopulmonary testing in adult patients with β-thalassemia major in comparison to healthy subjects.

Authors:  G Piatti; M Giuditta; D Consonni; E Cassinerio; M D Cappellini
Journal:  Ann Hematol       Date:  2022-09-13       Impact factor: 4.030

2.  Left ventricular torsional mechanics and myocardial iron load in beta-thalassaemia major: a potential role of titin degradation.

Authors:  Mei-Pian Chen; Shu-Na Li; Wendy W M Lam; Yuen-Chi Ho; Shau-Yin Ha; Godfrey C F Chan; Yiu-Fai Cheung
Journal:  BMC Cardiovasc Disord       Date:  2014-04-12       Impact factor: 2.298
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.